🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
43.11
+0.12 (0.28%)
At close: Nov 18, 2026, 4:00 PM EST
43.01
-0.10 (-0.23%)
After-hours: Nov 18, 2026, 5:02 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

REDEMPLO’s sHTG application could receive a decision in the March-April timeframe, supported by strong triglyceride and pancreatitis data. 2027 catalysts include ARO-DIMER and ARO-MAPT data, plus a potential zodasiran NDA filing.

Maury Raycroft
Analyst, Jefferies

Hi, everyone. My name is Maury Raycroft, and I am one of the Biotech Analysts at Jefferies. I would like to welcome Vince Anzalone.

Chris Anzalone
CEO, Arrowhead

No.

Maury Raycroft
Analyst, Jefferies

Or Chris, sorry, Chris Anzalone, the CEO of Arrowhead. Thanks so much for joining us today, Chris.

Chris Anzalone
CEO, Arrowhead

Sure, Craig.

Maury Raycroft
Analyst, Jefferies

Maybe to start off, for those who are new to the story, if you can give a one-minute intro to Arrowhead.

Chris Anzalone
CEO, Arrowhead

Sure. Thanks again for having us. It is always a pleasure to be here and to see all you folks. Arrowhead is an RNAi company, and we have spent the last 15+ years building out, I think the broadest platform in RNAi. We can now deliver to seven different cell types, and we have clinical studies in five of those cell types. We have 23 individual drug candidates in clinical study as we speak. About half of those are partnered, half are wholly owned. We have just launched our first drug earlier this year, called REDEMPLO. It is addressing familial chylomicronemia syndrome, or FCS. We just filed our sNDA to expand that to include severe hypertriglyceridemia. We have STAR designation, so we expect that to be approved in the March-April timeframe or so. Underneath that, we have a lot of other things we are working on.

We just recently announced data in ARO-MAPT. That is our siRNA molecule designed to knock down tau. Importantly, it is not intrathecal injection, it is subQ injection. We saw clinical proof of concept that we are capable of delivering to the brain, A, and B, that we are capable of knocking down MAPT or tau. That was exciting. We also have a program that is our first dimer. With a single molecule, we are knocking down both PCSK9 to lower LDL cholesterol and APOC3 to lower triglycerides. We expect to move that forward in mixed hyperlipidemia, and we see that as a real opportunity as well. Anyway, that is a thumbnail sketch of who we are right now.

Maury Raycroft
Analyst, Jefferies

Yeah, it is a great intro. You mentioned March approval, potentially?

Chris Anzalone
CEO, Arrowhead

Well, what they say is it is a six-month process, but they try to do it shorter than that. We will see when we get approved. The sNDA was filed November 2nd, and so sometime up to six months from then.

Maury Raycroft
Analyst, Jefferies

Talk a little bit about the STAR program and why FDA gave you that.

Chris Anzalone
CEO, Arrowhead

We're the first ones. We're excited about it because it was a reflection of the quality of the data that we saw in SHASTA-3 and 4, our phase III studies in sHTG patients. It was a reflection of the safety profile that we saw that was stellar. We believe that the FDA saw this as an important medicine that should get to patients as quickly as possible.

Maury Raycroft
Analyst, Jefferies

Just talk about the filing package, and are there issues on efficacy, safety, or CMC that could lead to additional FDA questions or potentially extend timelines?

Chris Anzalone
CEO, Arrowhead

Yeah, we don't expect that. It's not one of those nail-biting PDUFA dates, I don't think. The data in our phase III for FCS was crystal clear. It was unambiguous. The approval endpoint there was simply lowering triglycerides, and we were way overpowered for that. Same thing here for sHTG, just a slightly different patient population. It's a much broader patient population. We think there's between 3 million and 3.5 million people in the U.S. alone with triglycerides above 500 mg/dL. 150 mg/dL is normal. What we saw in SHASTA-3 and 4 was, again, continued consistent good efficacy. We saw an 80% reduction of triglycerides from baseline. I don't think anyone has ever seen anything like that before. We saw an improvement in rates of pancreatitis. That was important. We saw a good safety profile. Unlike our competitors, we don't see any increase in liver fat.

We don't see any meaningful increases in ALTs. We don't see any hypersensitivity, et cetera. This is dosed once a quarter. It feels to us like a drug that has a real place, and we look forward to getting there.

Maury Raycroft
Analyst, Jefferies

Got it. We've got the TRYNGOLZA label. What are areas of the proposed sHTG label where you think REDEMPLO could meaningfully differentiate from TRYNGOLZA, whether it's AP language, dosing, or monitoring?

Chris Anzalone
CEO, Arrowhead

Sure. The way I think of REDEMPLO is simple, safe, and strong. It's simple because it's a simple quarterly injection that does not require, we don't expect to require liver monitoring and then titrate up. TRYNGOLZA requires that. It is safe because we don't see any liver fat increases. We don't see hypersensitivity, as I say. We don't see thrombocytopenia. We don't see ALT increases. It's strong because we see 80% reduction from baseline of triglycerides. We saw a clear benefit in decreasing bouts of acute pancreatitis. Our NNT for that population with triglycerides above 500 mg/dL and history of pancreatitis was three. It was three. It takes three patients over the course of 12 months to stop one bout of pancreatitis, and we think that is a very compelling number. We have an ongoing study called SHASTA-5 that is a longer-term study.

It's an event-driven study in high-risk patients. I wouldn't be surprised if that NNT could shrink even further as we look out beyond one year of treatment.

Maury Raycroft
Analyst, Jefferies

Got it. Maybe a quick question on SHASTA-5. Is that study, you are going to keep running that to the end, or have you made any decisions on that?

Chris Anzalone
CEO, Arrowhead

Yeah, it is a good question. We are. You could argue that we do not need to because we saw an improvement in pancreatitis risk in SHASTA-3 and 4. You know what? We think that every time we see an improvement in pancreatitis, that is a good thing for the field. This is an education play. Physicians generally are not used to looking at triglycerides and thinking of them as bad actors and getting people on therapy. The more often we can show the real risk of pancreatitis in these patients, and the fact that we can lower that risk, I think is a good thing. We are continuing to operate that. We are seeing events, and so my expectation is that that goes into next year, and then we will see.

Maury Raycroft
Analyst, Jefferies

Got it. Ionis has had a relatively slow start with TRYNGOLZA, and they cut their guidance materially. What have you learned from their launch about where the challenges are, and how could you address those?

Chris Anzalone
CEO, Arrowhead

Sure. One is just communication. I think we need to be disciplined and not provide revenue guidance before we have a feeling for how payers are going to react to this. We are having discussions with payers as we speak. I think that is a good thing. My hope is that we can hit the ground running because we are having these discussions now. We hope there is not too much of a lag between being approved, and then having policies and then coverage. I think we can affect that. That is important. It is important that as we are launching, that we share important metrics, since revenue early on only tells part of the story. There are three big metrics that I think we will be talking about. One is number of prescriptions. That is a clear measurement of demand.

That has been high for FCS, even higher, in fact, than we expected, so that's a good start. Let's see how that goes with sHTG. Second would be number of prescribing physicians. We've seen good growth there also in FCS. Let's see where that goes with sHTG. Then, third would be number of covered lives. I think for FCS right now, I think we have covered lives of around 160 million or so. Let's see how fast we can ramp that up with sHTG. We are actively preparing for that launch, and we are, as we mentioned, speaking with payers. Also, us being out in the field with FCS physicians is also important for physicians to learn about the medicine, and how it can be used. Even though we are only selling into FCS, these physicians certainly have sHTG patients.

So, the more they're used to hearing about this and seeing the benefits of it, I think that will allow us to hit the ground running.

Maury Raycroft
Analyst, Jefferies

Got it. Ionis has about a 200-person field team in place. Would you have a similarly sized sales force?

Chris Anzalone
CEO, Arrowhead

Yeah, similar. Yeah. In fact, we have already largely ramped that up. We have a small additional wave that will be coming in January, but we are essentially Our commercial team is where it's going to be. Look, this is important. This launch has to be effective. This is a large market, a big opportunity, as I said, between 3 million and 3.5 million people with triglycerides above 500 mg/dL. Importantly, we think there's about 1 million very high-risk individuals. These would be people with triglycerides above 500 mg/dL with a history of pancreatitis, plus those above 880 mg/dL with no history of pancreatitis. There's a clear need to treat those patients. So, I think it's critical that we hit the ground running, and we get this into the patients who need it.

Maury Raycroft
Analyst, Jefferies

Got it. Just a clarification on that point. You had the detailed sHTG data recently in the New England Journal of Medicine publication. You showed a breakdown of AP and also at the AHA by subgroups. How do you think about that, the million patients out there that are high risk, and how many actually have documented prior AP?

Chris Anzalone
CEO, Arrowhead

Right. That's harder to come at than you would think. We think that there are probably a couple hundred thousand people with triglycerides above 500 mg/dL and history of pancreatitis. We don't know for sure because there are many reasons for pancreatitis. But, we think that TG-related pancreatitis is about that number. We think there's about 750,000 or 800,000 people with triglycerides above 880 mg/dL. That is a ticking time bomb because we know that as triglyceride levels increase, you see a fairly linear increase in the risk of pancreatitis. That slope steepens at 500 mg/dL and steepens again at 880 mg/dL. We think everybody above 500 mg/dL needs to get down below 500 mg/dL, and to the extent possible, to normalize at 150 mg/dL. But we absolutely believe that people above 880 mg/dL need to get down to below 880 mg/dL and preferably below 500 mg/dL.

Maury Raycroft
Analyst, Jefferies

Got it. How reliably can you identify that cohort in claims so the commercial team can target them from day one?

Chris Anzalone
CEO, Arrowhead

It's much easier to identify those folks based on triglyceride levels, right? Triglycerides are monitored in most lipid panels, so most patients have some history of TG levels. That's our primary gauge.

Maury Raycroft
Analyst, Jefferies

Anything else you can say on strategic differentiation versus Ionis in finding optimal patients at this point?

Chris Anzalone
CEO, Arrowhead

Yeah. I think they'll be targeting largely the same patient population that we will. I think that as we transition from FCS to sHTG, the patient profile changes. These sHTG patients are less symptomatic. I think in that kind of patient population, a clean safety profile is even more important. Convenience is even more important. Look, our primary strategy at launch and beyond is building the market, is finding new patients to the class and putting them on REDEMPLO. However, I think switches will, over time, be increasingly important, particularly when there does not seem to be a trade-off.

If somebody has been sticking themselves once a month for quite some time, and still worry about liver fat and still worries about transaminases and maybe hypersensitivity, if there's no downside to changing and limiting those risks, or even eliminating those risks, and also, oh, by the way, you stick yourself once a quarter, not once a month, I think that's pretty compelling for somebody who is not terribly symptomatic.

Maury Raycroft
Analyst, Jefferies

Got it. You said that the opportunity could be $3 billion-$4 billion. Can you run through your assumptions on how you get there?

Chris Anzalone
CEO, Arrowhead

Sure. There's a lot of ways to get there. That's $3 billion-$4 billion a year at peak in the United States. Again, just look at the high-risk individuals. Look at those patients with triglycerides above 500 mg/dL and a history of pancreatitis, plus those with trigs above 800 mg/dL. There's 1 million people who we believe are desperately in need of therapy. Remember, about 1 million people with triglycerides above 500 mg/dL are on prescription fish oils. While this is an education play, we're not starting from scratch because clearly that suggests to us that physicians see those million patients as requiring treatment. That's just prescription fish oils. That doesn't include over-the-counter. Just with that high-risk population, our list price is $45,000 a year. You can get to a fairly large number just penetrating that population.

I think, though, that as physicians become more accustomed to seeing triglycerides as bad actors, I think that the penetration starts to expand in that less severe population. Somebody with triglycerides at 600 mg/dL or 700 mg/dL with no history of pancreatitis, clearly that person is severely hypertriglyceridemic. Again, normal is 150 mg / dL. We think over time, we can start to penetrate that less severe market.

Maury Raycroft
Analyst, Jefferies

Got it. You mentioned the price at $45,000. That's at a 12.5% premium versus TRYNGOLZA. Talk about that and whether payers are on board with the increased value proposition, or do you have to do more discounting in the background?

Chris Anzalone
CEO, Arrowhead

Yeah. We'll see where it goes with sHTG. We aren't doing very much discounting at all in FCS. The way we view it is, look, it is unfortunate that triglycerides show up on a regular lipid panel because it makes people think of it as a lipid drug. You run to comps would be PCSK9 inhibitors. It's nothing like that. This is not an ASCVD drug. This is a pancreatitis drug. We've always viewed this more analogous to a MASH drug. Given the strength of REDEMPLO, the extent of triglyceride lowering, the extent of AP risk reduction, the clean safety profile, we think there's a ton of differentiation there between TRYNGOLZA and REDEMPLO that we should price at a premium.

Maury Raycroft
Analyst, Jefferies

Got it. Let's talk about some of the data with the LDL. You see an increase there across the class, although you guys are increasing less than TRYNGOLZA. Given that 69% of SHASTA patients were on statins and baseline LDL was slightly controlled, what happens in the real world patients whose LDL starts at a much higher level than the less than 70 mg/dL? Are there patients where you would expect clinicians to intensify LDL treatment before starting?

Chris Anzalone
CEO, Arrowhead

Yeah. Let's see where that goes. We are not super concerned with that because when we do see increases in LDL, it is at very, very high levels of triglycerides, in the thousands. Those patients generally have low LDL to begin with, quite low, in fact. In the more traditional severe hypertriglyceridemia market of between 500 mg/dL and 800 mg/dL or so, you do not see much movement in LDL.

Maury Raycroft
Analyst, Jefferies

Makes sense. Going back to SHASTA-5, once you get that data, if it is successful, could that actually increase the value proposition? Could you potentially increase your price based on that?

Chris Anzalone
CEO, Arrowhead

I do not think so. I think that data will be nice to have for marketing in Europe, and also just increasing the story that we are capable of decreasing the risk of pancreatitis.

Maury Raycroft
Analyst, Jefferies

Got it. FCS, it is ultra-rare, but your launch looks strong in the leading indicators, including patient starts and prescriber breadth. But revenue conversion is taking longer. Are there technical issues behind this, or what are some of the explanations there?

Chris Anzalone
CEO, Arrowhead

No, it is just time. It has just taken us a little bit of time to have policies in place and have coverage in place to make that process smooth from a prescription being written and a paid shipment. For me, I am not worried that that will not happen. I am just more focused on getting that to happen more quickly. We are getting there. We have had breakthroughs with payers over the last couple weeks to keep that moving. We feel good about that.

Maury Raycroft
Analyst, Jefferies

Got it. Just as greater awareness around the drug spreads out there and with the sHTG data that is out there, would you expect to see an inflection in FCS over the next two quarters ahead of your approval for sHTG?

Chris Anzalone
CEO, Arrowhead

I do not know the answer to that. I would not expect to see a big uptick in prescriptions compared to now. I think we will continue to see good increases. We are at 50 to 60 new prescriptions every week. That feels pretty good. We have competition in sHTG now that would make it easier for some physicians just to prescribe TRYNGOLZA rather than REDEMPLO, right. That is a, I guess that is a confounding influence. I would expect continued growth, but not an inflection point necessarily between now and March- April.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Let's shift gears, talk about some of the other programs in the pipeline with ARO-DIMER. I thought the data at AHA looked good with the SAD data showing that you can get knockdown as good as single agents. When should we expect to see the MAD data, and what efficacy, duration, and tolerability are you looking for?

Chris Anzalone
CEO, Arrowhead

Yeah. We'll have MAD data in likely the first half of 2027. As you say, we were really encouraged by that. The idea was this. We know the PCSK9 inhibition is a good lowering agent of LDL, and LDL is the most validated biomarker on God's green earth. We thought if we could add to that the ability to lower APOC3, and therefore lower triglycerides, we could treat this mixed hyperlipidemia population that has both elevated LDL and triglycerides in a more complete fashion. There's an awful lot of evidence that triglyceride-rich lipoproteins, remnant cholesterol, are all potentially more atherogenic even than LDL cholesterol. It's never been interrogated because no one's been able to lower triglycerides to the extent that we can. We thought if you combine those two, you've got something that could be very powerful.

From a regulatory pathway standpoint, we believe that we can see approval based solely on LDL reduction. All the PCSK9s were first approved solely on LDL reduction. That is a fairly rapid to registration path. That's a year-long study. I think we can start that phase III fairly quickly. What comes out the other side of this is a complete, or a quote, unquote, complete therapy, for these mixed hyperlipidemia patients. The value proposition is you get similar LDL reduction as you get with the PCSK9s, but oh, by the way, you get triglyceride reduction for free. That's pretty compelling, and will allow us to treat a whole swath of folks. We think about 20 million people in the U.S. with mixed hyperlipidemia where there is not that complete treatment.

Maury Raycroft
Analyst, Jefferies

Makes sense. The two targets, they generally move together, but there's a lot of patient heterogeneity out there. How much patient level variability is acceptable before the fixed ratio nature of the dimer becomes a limitation?

Chris Anzalone
CEO, Arrowhead

We're not so worried about that. What we have seen is similar knockdown potency for both APOC3 and PCSK9, so I don't think that's going to be a limiting factor. What we are focused on in the SAD and what we will be focused on in the MAD is not just LDL reduction and triglyceride reduction, but ApoB reduction. ApoB is probably the truer marker of how we're doing. At least so far, after SAD, we see better ApoB reduction than PCSK9 inhibitors and quite similar LDL reduction as PCSK9 inhibitors. I think we're off to a great start.

Maury Raycroft
Analyst, Jefferies

Maybe talk about the registrational path a little bit more. I guess, what would be the fastest path and the cleanest, or the exact population that would get to the cleanest results?

Chris Anzalone
CEO, Arrowhead

Right. The population would be those patients with mixed hyperlipidemia, elevated LDL and elevated triglycerides. What that means, we'll see. Is that LDL above 70 mg/dL or LDL above 55 mg/dL? We'll see. Then triglycerides, most patients will probably be in the 200 mg/dL to 250 mg/dL range or so, but of course, we'll go all the way up to 499 mg/dL. There's a lot of those patients out there, so I don't think recruiting that's going to be difficult. An LDL biomarker study would be a year-long study, so I think we could enroll that quite quickly and get through that quite quickly.

Maury Raycroft
Analyst, Jefferies

Got it. Let's talk about the ARO-MAPT. You showed nice proof of concept there with subQ delivery. What are next steps for that program, and when could we potentially get a data update in 2027?

Chris Anzalone
CEO, Arrowhead

Yeah, those are really exciting data, and those are just single exposure data. We will have MAD data in the first half, I guess, of 2027 in healthy volunteers. What we saw was good knockdown of tau as assessed in the cerebrospinal fluid. I think that only tells part of the story, though, right. We're seeing good knockdown, but what we assume we are also seeing is broad distribution. What we saw in non-human primates was broad, consistent distribution around the brain and knocking down tau. That's super important. If you do an intrathecal injection, you'll see a lot of knockdown in the cord, and then maybe a little bit north of that, but you don't see a lot of broad brain coverage. We expect to get that. Again, we had that in NHPs.

Let's see what the MAD data look like, but we're off to a really good start. There's increasingly good data coming out of Biogen in Alzheimer's. In fact, just yesterday, there was more data there that looked quite encouraging. Also, let's remember that there are other primary tauopathies that we can go after where there's a faster regulatory pathway. Look at PSP, look at FTD. My expectation is that we could potentially start a phase III in FTD sometime towards the end of next year. That would be a relatively fast study, and a relatively quick way to get this into patients who need it relatively fast.

Maury Raycroft
Analyst, Jefferies

Yeah. Makes sense. Let's talk about obesity briefly. You're going to have a data update by year end. Talk about how many patients we should expect at that update, and have you gotten regulatory clarity on next steps for this program?

Chris Anzalone
CEO, Arrowhead

Sure. Yeah. We'll have more data on INHBE and ALK7. INHBE is the liver target, ALK7 is adipose target. We haven't shown much ALK7 data yet, so that'll be the bigger- The bigger disclosure, I guess. INHBE is looking more and more like a MASH drug. We're seeing better than 60% or 70% or so reduction in liver fat with INHBE in combination with tirzepatide. It was really stunning. So, we are exploring what phase IIs would look like in MASH there. ALK-7, we're looking forward to seeing these data and potentially pushing those forward into other obesity studies in 2027.

Maury Raycroft
Analyst, Jefferies

Got it. In closing, talk about whether there could be additional BD and key catalysts ahead that investors should be focused on.

Chris Anzalone
CEO, Arrowhead

Sure. Yes, there could be more BD ahead. We have this discovery engine that is second to none and extraordinarily productive. We can do things that no one else can do. We can deliver oligonucleotides to the brain. We know that now in humans. I think there is a lot of value there. We can deliver to adipose tissue. We can deliver to muscle, to cardiomyocytes, to liver, of course. We have good broad coverage, so I think there are good discovery partnerships to be done there. On catalysts, we will have more obesity data by the end of this year. We will have data in Alzheimer's patients with MAPT throughout 2027, both knockdown as well as tau PET data. We will have more dimer data in the first half, I guess, of 2027, in mixed hyperlipidemia patients.

We think that we could see an approval of REDEMPLO in sHTG in March, April timeframe, something like that. We do not have our PDUFA date yet, but something around then. We will complete the phase III study of zodasiran. That is our ANGPTL3 program against HoFH. That phase III will be done sometime in the middle of the year, so my expectation is we will file an NDA there by the end of next year. That is a big move. Then let's see how the REDEMPLO launch goes. As I mentioned, we are focused on that like a laser, and my expectation is that that should be a good launch.

Maury Raycroft
Analyst, Jefferies

Chris, thanks so much for joining us today. Great speaking with you.

Chris Anzalone
CEO, Arrowhead

Thank you.